Tags

Type your tag names separated by a space and hit enter

Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2.
Int Immunopharmacol. 2021 Jan; 90:107172.II

Abstract

The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19.

Authors+Show Affiliations

CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China; University of Chinese Academy of Sciences, Beijing, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.Department of Laboratory Medicine, The People's Hospital of Suzhou New District, Suzhou, China.Acrobiosystems Inc, Beijing, China.Acrobiosystems Inc, Beijing, China.Acrobiosystems Inc, Beijing, China.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: szliyong@sibet.ac.cn.CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: weiss@sibet.ac.cn.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33191178

Citation

Wei, Shuangshi, et al. "Chicken Egg Yolk Antibodies (IgYs) Block the Binding of Multiple SARS-CoV-2 Spike Protein Variants to Human ACE2." International Immunopharmacology, vol. 90, 2021, p. 107172.
Wei S, Duan S, Liu X, et al. Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. Int Immunopharmacol. 2021;90:107172.
Wei, S., Duan, S., Liu, X., Wang, H., Ding, S., Chen, Y., Xie, J., Tian, J., Yu, N., Ge, P., Zhang, X., Chen, X., Li, Y., & Meng, Q. (2021). Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. International Immunopharmacology, 90, 107172. https://doi.org/10.1016/j.intimp.2020.107172
Wei S, et al. Chicken Egg Yolk Antibodies (IgYs) Block the Binding of Multiple SARS-CoV-2 Spike Protein Variants to Human ACE2. Int Immunopharmacol. 2021;90:107172. PubMed PMID: 33191178.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. AU - Wei,Shuangshi, AU - Duan,Shengbao, AU - Liu,Xiaomei, AU - Wang,Hongmei, AU - Ding,Shaohua, AU - Chen,Yezhou, AU - Xie,Jinsong, AU - Tian,Jingjing, AU - Yu,Nong, AU - Ge,Pingju, AU - Zhang,Xinglin, AU - Chen,Xiaohong, AU - Li,Yong, AU - Meng,Qinglin, Y1 - 2020/11/03/ PY - 2020/09/15/received PY - 2020/10/24/revised PY - 2020/10/30/accepted PY - 2020/11/17/pubmed PY - 2021/1/29/medline PY - 2020/11/16/entrez KW - Chicken Egg Yolk Antibodies KW - IgY KW - Neutralizing agent KW - SARS-CoV-2 KW - Spike protein variants SP - 107172 EP - 107172 JF - International immunopharmacology JO - Int Immunopharmacol VL - 90 N2 - The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/33191178/Chicken_Egg_Yolk_Antibodies__IgYs__block_the_binding_of_multiple_SARS_CoV_2_spike_protein_variants_to_human_ACE2_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(20)33639-0 DB - PRIME DP - Unbound Medicine ER -